Verastem Oncology (NASDAQ: VSTM) announced it will discontinue the RAMP 203 Phase 1/2 clinical trial for advanced KRAS G12C-mutated non-small ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE